• Price (USD)123.44
  • Today's Change-0.52 / -0.42%
  • Shares traded270.29k
  • 1 Year change-28.73%
  • Beta0.5873
Data delayed at least 15 minutes, as of Nov 25 2022 18:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

  • Revenue in USD (TTM)1.86bn
  • Net income in USD-636.77m
  • Incorporated1997
  • Employees2.68k
  • Location
    Seagen Inc21823 30Th Drive Se, SuiteBOTHELL 98021United StatesUSA
  • Phone+1 (425) 527-4000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.seagen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Charles River Laboratories Intl. Inc3.78bn436.39m12.36bn18.60k28.614.7016.773.278.498.4973.6051.630.523710.705.28203,293.906.146.617.177.8537.3137.1511.7210.931.1418.980.52380.0021.0816.067.3220.4132.85--
BIO-TECHNE Corp1.12bn291.88m13.30bn3.00k47.487.5934.3911.907.147.1427.3244.640.48372.646.95372,511.7012.298.4713.089.0368.4667.2325.4019.872.92--0.131329.5218.7514.4593.7929.0124.230.00
Viatris Inc16.73bn803.60m13.51bn37.00k16.890.70423.640.80760.65970.659713.7715.820.31952.555.02452,116.201.53-0.36851.82-0.442843.1938.974.80-
Incyte Corporation3.33bn876.05m17.41bn2.09k19.894.1218.515.233.943.9414.9219.000.68615.075.871,590,634.0018.055.8922.017.0594.8995.8826.307.983.758.870.00790.0011.9821.98420.8055.538.52--
Horizon Therapeutics PLC3.81bn764.96m17.74bn2.02k24.183.6515.454.653.243.2416.1421.470.4474.065.412,017,520.008.973.939.924.6475.3971.3720.0610.983.7911.270.34170.0046.6326.8837.12--37.25--
ICON PLC7.66bn464.33m17.88bn40.50k38.942.1717.282.335.625.6292.79100.910.4407--3.63199,961.002.697.223.149.5328.2230.266.109.57--4.080.3706--95.9326.88-53.91-10.1917.09--
Biomarin Pharmaceutical Inc2.01bn79.99m18.01bn3.05k245.493.9498.228.970.39480.416210.6924.590.32810.59935.06659,543.801.31-0.9721.43-1.1276.2976.743.98-2.913.540.04830.1915---0.762210.58-1,590.90---4.28--
Seagen Inc1.86bn-636.77m22.92bn2.68k--8.10--12.29-3.46-3.4610.1415.230.49081.424.27696,864.70-16.76-5.22-20.63-6.0079.1687.67-34.16-9.783.30-142.610.00---27.6330.36-209.91--13.46--
Alnylam Pharmaceuticals, Inc.960.92m-1.18bn26.17bn1.67k------27.23-9.77-9.777.95-0.54990.27431.456.86577,127.90-33.74-32.56-42.04-37.9483.85---123.02-223.643.33-2.761.07--71.3178.070.6358--3.42--
Gartner Inc5.28bn760.34m27.07bn16.60k36.95--28.345.139.279.2764.37-0.82010.7807--5.11317,918.8011.254.1220.197.0669.3465.0014.416.65--15.861.03--15.4814.13197.5032.603.71--
Data as of Nov 25 2022. Currency figures normalised to Seagen Inc's reporting currency: US Dollar USD

Institutional shareholders

59.42%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 30 Sep 202246.91m25.27%
Capital Research & Management Co. (International Investors)as of 30 Sep 202215.56m8.38%
The Vanguard Group, Inc.as of 30 Sep 202212.37m6.66%
Wellington Management Co. LLPas of 30 Sep 20229.84m5.30%
BlackRock Fund Advisorsas of 30 Sep 20227.96m4.29%
Capital Research & Management Co. (World Investors)as of 30 Sep 20224.68m2.52%
PRIMECAP Management Co.as of 30 Sep 20224.58m2.47%
SSgA Funds Management, Inc.as of 30 Sep 20223.46m1.86%
JPMorgan Investment Management, Inc.as of 30 Sep 20222.49m1.34%
Fidelity Management & Research Co. LLCas of 30 Sep 20222.47m1.33%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.